New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Issuers›VIRTUS Investment Partners›BBP
BBP

Virtus LifeSci Biotech Products ETF

Passive ETFEquityTheme: Tomorrow's Treatments

The BBP Exchange Traded Fund (ETF) is provided by VIRTUS Investment Partners. It is built to track an index: LifeSci Biotechnology Products Index. The BBP ETF provides physical exposure, so by buying it you actually own parts of all the 66 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$97.73
+$0.47 (+0.48%) today
2:43 PM 07/27/26 Open
1D price range
$96.35$96.90
52W price range
$61.61$103.52
YTD Perf.
+20.72%
YTD Flows
Annualized volatility
Fund AuM
€85M
Share class AuM
€85M
TTM Yield
Tracking Error
Tracking Difference
Characteristics
ISIN
US26923G2021
TER
0.34%
Inception date
12/16/2014
Issuer
VIRTUS Investment Partners
Benchmark
LifeSci Biotechnology Products Index
Replication method
Dividend policy
Distributing
Compare similar ETFs
ETF Name1w perf.
GNOG
Global X Genomics & Biotechnology UCITS ETF
-1.77%
GNOM
Global X Genomics & Biotechnology ETF
-1.78%
FMED
Fidelity Disruptive Medicine ETF
-1.68%
CANC
Tema Oncology ETF
+0.13%
HELX
Franklin Genomic Advancements ETF
-1.68%
SBIO
ALPS Medical Breakthroughs ETF
-2.18%
OZEM
Roundhill GLP-1 & Weight Loss ETF
+0.05%
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
+0.31%
BBC
Virtus LifeSci Biotech Clinical Trials ETF
-2.92%
MEDX
Horizon Kinetics Medical ETF
+0.48%
THNR
Amplify Weight Loss Drug & Treatment ETF
-0.36%
ASD
Defiance Autism Impact ETF
-0.97%
API
PerformanceDec 31, 2025 - Jul 24, 2026
-5%0%5%10%15%20%25%30%JANMARMAYJUL
Flows
Join for free to unlock
Sector exposures
Data as of 06/30/26
Healthcare
89.47%
Unavailable
10.53%
Latest BBP news

No content available for this fund

FAQ about BBP

BBP is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
BBP tracks the LifeSci Biotechnology Products Total Return Index - USD, through a full replication replication method.
BBP carries a total expense ratio (TER) of 0.34%, indicating the annual cost for holding the fund.
BBP was introduced to the market on December 16, 2014. It trades on United States
Virtus LifeSci Biotech Products ETF, BBP, is provided by VIRTUS Investment Partners. Learn more about VIRTUS Investment Partners here.
BBP oversees €85M in assets as of July 24, 2026.
BBP follows a distributing dividend policy, meaning it pays out income to investors.
As of June 30, 2026, BBP has significant geographic allocations in USA.
As of June 30, 2026, BBP focuses largely on Healthcare.
As of June 30, 2026, BBP holds 66 positions in its portfolio, with 87.15% of assets concentrated in its top 15 holdings.
As of June 30, 2026, BBP top three holdings include Verastem, Inc., Legend Biotech Corp. and Harmony Biosciences Holdings, Inc..
The base currency of BBP is USD.
Top 10 holdings
Data as of 06/30/26
Verastem, Inc.
44.58%
Legend Biotech Corp.
41.98%
Harmony Biosciences Holdings, Inc.
0.05%
Regeneron Pharmaceuticals, Inc.
0.05%
Axsome Therapeutics, Inc.
0.05%
BioMarin Pharmaceutical, Inc.
0.05%
Moderna, Inc.
0.05%
Ultragenyx Pharmaceutical, Inc.
0.05%
Arrowhead Pharmaceuticals, Inc.
0.05%
Roivant Sciences Ltd.
0.05%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
ETF TOOLS
ETF ScreenerCompare ETFsCompare ETF issuersWatchlistsETF Portfolio InsightsIndustry dataETF stock exposure finder
PLATFORM
Support and feedback
ETF NEWS & RESEARCH
Latest ETF NewsETF Research ReportsGlobal ETF Survey 2025Learn ETF investing
PROFESSIONAL SOLUTIONS
Enterprise SolutionsDue Diligence ServicesETF Data Services
SOLUTIONS FOR
Institutional investorsPrivate banksFinancial advisorsFintech and mediaIndividual investors
CONTACT US
General inquiries
Press and media
Advertising opportunities
Support and feedback
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Get our newsletters
Trackinsight